TCGA-LL-A6FR-01A-12R-A31O-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 16
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.380
- COAGULATION+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- KRAS_SIGNALING_DN+0.360
- PANCREAS_BETA_CELLS+0.360
- HYPOXIA+0.300
- NOTCH_SIGNALING+0.280
- GLYCOLYSIS+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
- APICAL_SURFACE+0.190
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- MITOTIC_SPINDLE-0.400
- ANDROGEN_RESPONSE-0.360
- UV_RESPONSE_DN-0.340
- IL6_JAK_STAT3_SIGNALING-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- PI3K_AKT_MTOR_SIGNALING-0.260
- HEME_METABOLISM-0.240
- TGF_BETA_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195687 | — | — | 0.795 |
| 2 | SRR25617841 | — | E | 0.787 |
| 3 | MDT-AP-2153 | Med | Medulloblastoma | 0.760 |
| 4 | GSM6454752 | — | E | 0.755 |
| 5 | 16ab68fd-4948-4cd5-b5d8-1b2e8a1fd3cb | — | — | 0.751 |
| 6 | TCGA-77-A5G8-01B-11R-A27Q-07 | — | cohortSQ2 | 0.749 |
| 7 | TCGA-GU-A767-01A-11R-A32O-07 | — | — | 0.740 |
| 8 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.736 |
| 9 | SRR2016952 | — | — | 0.735 |
| 10 | SAMN03290888 | — | — | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.050 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |